Nodal Marginal Zone Lymphoma
📧 Sign up to get email alerts when something new happens for Nodal Marginal Zone Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-10-28Clinical Trial Update: Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) [Phase 2]
Phase 2 clinical trial update for epcoritamab in newly diagnosed marginal zone lymphoma, currently recruiting across MZL subtypes.
-
CLINICAL_TRIALS trial_result · 2023-03-21Clinical Trial Update: Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas [Phase 2]
Phase 2 trial of pembrolizumab alone or with idelalisib or ibrutinib in relapsed/refractory chronic lymphocytic leukemia or various low-grad…
-
CLINICAL_TRIALS trial_result · 2018-03-06Clinical Trial Update: Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial evaluating vorinostat in multiple low-grade non-Hodgkin lymphomas, including MALT lymphoma, nodal marginal zone lymphoma, foll…
-
CLINICAL_TRIALS trial_result · 2017-11-06Clinical Trial Update: Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma [Phase 3]
Phase 3 trial evaluating BCD-020 for indolent non-Hodgkin lymphomas has completed, assessing safety and efficacy.
-
CLINICAL_TRIALS trial_result · 2017-10-09Clinical Trial Update: Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma [Phase 2]
Phase 2 clinical trial evaluating the combination of pegfilgrastim and rituximab in patients with untreated, relapsed, or refractory follicu…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-05-22Clinical Trial Update: Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma [Phase 2]
Phase 2 study evaluating rituximab plus dexamethasone in patients with low-grade non-Hodgkin lymphoma, including follicular and marginal zon…
-
CLINICAL_TRIALS trial_result · 2015-02-18Clinical Trial Update: Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma [Phase 2]
A Phase 2 trial evaluating Rituximab with chemotherapy and 90-yttrium ibritumomab tiuxetan in patients with Stage I or II non-Hodgkin lympho…
-
CLINICAL_TRIALS trial_result · 2015-01-27Clinical Trial Update: Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating rituximab, cyclophosphamide, bortezomib, and dexamethasone in relapsed/refractory low-grade follicular lym…
-
CLINICAL_TRIALS trial_result · 2014-12-23Clinical Trial Update: Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms [Phase 1]
A Phase 1 trial evaluating the combination of bortezomib and flavopiridol in patients with recurrent or refractory indolent B-cell neoplasms…
-
CLINICAL_TRIALS trial_result · 2011-12-07Clinical Trial Update: Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma [Phase 2]
Phase 2 clinical trial evaluating tipifarnib in relapsed or refractory lymphoma has completed with results posted in 2011.